Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

证券之星消息，11月28日医疗器械板块较上一交易日上涨1.13%，康为世纪领涨。当日上证指数报收于 3888.6，上涨0.34%。深证成指报收于12984.08，上涨0.85%。医疗器械板块个股涨跌见下表： 从资金流向上来看，当日医疗器械板块主力资金净流出1.73亿元，游资资金净流入1.57亿元，散户资金净 流入1555.9万元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688426 | 康为世纪 | 27.86 | 5.17% | 1.85万 | 5041.76万 | | | 300760 | 迈瑞医疗 | 204.01 | 3.93% | 11.78万 | | 23.78亿 | | 300677 | 英科医疗 | 43.07 | 3.71% | 17.93万 | | 7.61亿 | | 600807 | 济高发展 | 3.47 | 2.97% | 18.09万 | 6171.85万 | | | 300246 | 宝菜特 | 8.71 | ...

圆信永丰医药健康A（006274）成立日期2018年11月29日，最新规模3.87亿。今年以来收益35.33%，同 类排名1785/8127；近一年收益28.92%，同类排名2394/8059；成立以来收益128.56%。 圆信永丰医药健康A（006274）基金经理为肖世源。 11月28日，康为世纪涨5.13%，截至发稿，报27.85元/股，成交3996.93万元，换手率3.88%，总市值 31.33亿元。 资料显示，江苏康为世纪生物科技股份有限公司位于江苏省泰州市医药高新区泽兰路18号，成立日期 2010年9月3日，上市日期2022年10月25日，公司主营业务涉及分子检测产品的研发、生产和销售,并提 供分子检测服务。主营业务收入构成为：销售商品89.14%，提供服务10.86%，其他(补充)0.00%。 从康为世纪十大流通股东角度 数据显示，圆信永丰基金旗下1只基金位居康为世纪十大流通股东。圆信永丰医药健康A（006274）三 季度增持27.72万股，持有股数95万股，占流通股的比例为2.5%。根据测算，今日浮盈赚取约129.2万 元。 截至发稿，肖世源累计任职时间8年163天，现任基金资产总规模22.72 ...

康为世纪发行费用共计8,645.43万元，中信证券股份有限公司获得保荐承销费用6,448.68万元。 中信证券投资有限公司（参与跟投的保荐机构相关子公司）获配股数为931,611股，占首次公开发 行股票数量的比例为4.00%。 2023年6月6日，康为世纪公告分红方案，每10股派息(税前)5.2元，转增2股。股权登记日为2023 年6月9日，除权除息日为2023年6月12日。 （责任编辑：徐自立） 中国经济网北京11月27日讯 康为世纪(688426.SH)今日收报26.49元，跌幅4.71%。目前该股处于 破发状态。 康为世纪于2022年10月25日在上交所科创板上市，发行价格为48.98元/股，公开发行股份 2,329.0278万股，公司股东不公开发售股份，公开发行的新股占发行后总股本的25%，保荐机构（主 承销商）为中信证券股份有限公司，保荐代表人为杨凌、姜浩。 康为世纪上市发行募集资金总额为114,075.78万元，扣除发行费用后，募集资金净额为105,430.36 万元。康为世纪最终募集资金净额比原计划多6862.77万元。2022年10月20日，康为世纪发布的招股 书显示，公司拟募集资金98,56 ...

| 交易日 | 两融余额(元) | 余额变动 (元) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-26 | 1.32亿 | 205.72万 | 1.58% | | 2025-11-25 | 1.30亿 | 896.86万 | 7.42% | | 2025-11-24 | 1.21亿 | 210.34万 | 1.77% | | 2025-11-21 | 1.19亿 | 402.56万 | 3.51% | | 2025-11-20 | 1.15亿 | -286.29万 | -2.43% | 小知识 证券之星消息，11月26日，康为世纪（688426）融资买入2264.24万元，融资偿还2058.53万元，融资净 买入205.72万元，融资余额1.32亿元，近3个交易日已连续净买入累计1312.92万元，近20个交易日中有 12个交易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-11-26 | 205.72万 | 1.32亿 | 12.49% | | 20 ...

康为世纪发行费用共计8,645.43万元，中信证券股份有限公司获得保荐承销费用6,448.68万元。 中信证券投资有限公司(参与跟投的保荐机构相关子公司)获配股数为931,611股，占首次公开发行股 票数量的比例为4.00%。 2023年6月6日，康为世纪公告分红方案，每10股派息(税前)5.2元，转增2股。股权登记日为2023年6 月9日，除权除息日为2023年6月12日。 中国经济网北京11月26日讯 康为世纪(688426.SH)今日收报27.80元，跌幅10.78%。目前该股处于破 发状态。 康为世纪于2022年10月25日在上交所科创板上市，发行价格为48.98元/股，公开发行股份 2,329.0278万股，公司股东不公开发售股份，公开发行的新股占发行后总股本的25%，保荐机构(主承销 商)为中信证券股份有限公司，保荐代表人为杨凌、姜浩。 康为世纪上市发行募集资金总额为114,075.78万元，扣除发行费用后，募集资金净额为105,430.36万 元。康为世纪最终募集资金净额比原计划多6862.77万元。2022年10月20日，康为世纪发布的招股书显 示，公司拟募集资金98,567.59万元，分别用 ...

Market Overview - The medical device sector experienced a decline of 0.38% on November 26, with Kangwei Century leading the drop [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Top Performers - Haobor (688656) saw a significant increase of 9.38%, closing at 201.80 with a trading volume of 17,200 lots [1] - Shuoshi Biology (6668889) rose by 4.04%, closing at 69.82 with a trading volume of 21,500 lots [1] - Lexin Medical (300562) increased by 3.88%, closing at 14.20 with a trading volume of 107,400 lots [1] Underperformers - Kangwei Century (688426) fell by 10.78%, closing at 27.80 with a trading volume of 33,000 lots [2] - Boxin Biology (920504) decreased by 5.98%, closing at 22.97 with a trading volume of 8,514 lots [2] - Zhengchuan Co. (603976) dropped by 5.25%, closing at 21.30 with a trading volume of 33,800 lots [2] Capital Flow - The medical device sector saw a net outflow of 371 million yuan from institutional investors, while retail investors contributed a net inflow of 43.54 million yuan [2][3] - The top net inflows from institutional investors were seen in Lexin Medical (300562) with a net outflow of 33.13 million yuan [3] - The highest net inflow from retail investors was in Yuyue Medical (002223) with a net inflow of 24.16 million yuan [3]

Group 1 - The Sci-Tech 50 Index opened lower on November 26 but later rose significantly, closing at 1315.04 points with a gain of 0.99% and a trading volume of approximately 57.58 billion yuan [1] - The Sci-Tech Comprehensive Index also increased by 0.83%, closing at 1560.57 points with a total trading volume of about 182.8 billion yuan [2] - Excluding suspended stocks, the remaining 589 stocks on the Sci-Tech board showed an average decline of 0.15% with an average turnover rate of 2.66% [2] Group 2 - Semiconductor and biopharmaceutical stocks were notably active, while aviation and software service stocks experienced the largest declines [2] - Individual stock performance included Mingwei Electronics, Changguang Huaxin, Jindike, and Dongxin Co., which all hit the daily limit up, while Kangwei Century saw the largest drop at 10.78% [2] - In terms of trading volume, Hanwujing led with 11.89 billion yuan, while ST Guandian had the lowest at 1.027 million yuan [2] Group 3 - The turnover rate for Aerospace Huanyu was the highest at 31.51%, while Weigao Orthopedics had the lowest at 0.18% [3]

Group 1 - The company has obtained EU CE-IVDR certification and is exporting to multiple EU countries, including Croatia, Italy, Slovakia, and Hungary [2]

Core Viewpoint - 康为世纪 experienced a 5.13% increase in stock price, reaching 32.80 yuan per share, with a total market capitalization of 3.69 billion yuan as of November 17 [1] Company Overview - 江苏康为世纪生物科技股份有限公司 was established on September 3, 2010, and went public on October 25, 2022 [1] - The company specializes in the research, production, and sales of molecular detection products, providing molecular detection services [1] - Revenue composition: 89.14% from product sales, 10.86% from services, and 0.00% from other sources [1] Shareholder Analysis - 融通健康产业灵活配置混合A/B (000727) reduced its holdings by 1 million shares in Q3, now holding 2.6 million shares, representing 6.84% of the circulating shares [2] - The fund has achieved a year-to-date return of 16.85% and a one-year return of 6.21% [2] - The fund manager, 万民远, has a tenure of 9 years and 86 days, with a total fund size of 5.96 billion yuan [2][4] Fund Holdings - 融通价值成长混合A (015553) reduced its holdings by 50,000 shares in Q3, currently holding 450,000 shares, which is 3.05% of the fund's net value [3] - The fund has a year-to-date return of 24.83% and a one-year return of 19.23% [3] - The fund manager, 万民远, has a tenure of 9 years and 86 days, managing a total fund size of 5.96 billion yuan [4]